- Apple Surpasses Nokia as Top Handset Maker by Profit
- Three Things the US Can Do To Stop the Dollar's Decline
- Toll Brothers: More Contracts Signed, but Sales Down
- Fed's Lacker: US in a 'Good Place' With Inflation
- Bear Stearn Fund Managers Not Guilty on All Counts
- Commodity ETFs: Returns May Not Match Expectations
- JPMorgan Chase to Hire 1,200 Mortgage Officers
- Ponzi Proceeds: Bidding on Madoff's Toys
- Quiz: Do You Know Your Coca-Cola Myths?
- Beware of 'Trampling Effect' When Market Tops: Manager
- Gold Heading to $1150: Art Hogan
- Starbucks Brews Up Growth
- Farr: An Extended Period—No Fat Lady in Sight
- More Upside if S&P Passes This Number: Market Pro
- Murdoch Lashes Out At Google
- Fighting The Flu Vaccine Critics
- Nov. 10: Unusual Volume Leaders
- Shadow Inventory Dwarfs Loan Mods
- Logitech to buy LifeSize Communications for $405M
- Werner Enterprises to pay special dividend
- Emdeon 3Q loss widens on costs
- Ambac warns it may file for bankruptcy protection
- UN chief prods US Senate to tackle climate change
- Cliffs Natural raises quarterly dividend
- Atmos posts 4Q loss on drop in natural gas prices
- PepsiCo withdraws FTC filings in bottler deals
- Bob Evans 2Q profit rises 37 percent
Text Size 
NEW YORK - Sanofi-Aventis and Regeneron Pharmaceuticals Inc. said Tuesday they expanded an existing development partnership to run through 2017.
Initially, the partnership signed in 2007 was set to end in 2012.
Under the expanded deal, the companies plan on advancing up to five antibodies into clinical development each year, with Sanofi-Aventis funding up to $160 million annually for Regeneron research until the end of 2017 — up from prior funding levels of $100 million annually.
The companies have so far pushed four potential drugs into clinical development, aimed at conditions ranging from rheumatoid arthritis and pain, to advanced malignancies.
Shares of Sanofi-Aventis, headquartered in Paris, fell 2 cents to close at $37.89.
Shares of Regeneron, headquartered in Tarrytown, N.Y., rose 33 cents, or 2.1 percent, to reach $16.13 in after-hours trading after gaining 12 cents to close at $15.80 during the regular trading session.
Print
Email
- Vote and suggest your own, and remember--there's a fine line between a hero and a zero.
- If you are lucky enough to have money and the time, this is a great time to see America, says CNBC's Jane Wells.
- What’s powering your microwave, fridge and computer? Part of it is fuel from Russian nuclear weapons. The NYT reports.
- One author sees lessons for you in Disney’s recent Makeover of Mickey Mouse: “Nice” doesn’t always win.
- With 123 years of history, slogans and commercials, Coca-Cola is the most recognized brand on earth.
- The opening of a virtual pet store in “World of Warcraft” could prove a cash bonanza for Activision-Blizzard.
Data is a real-time snapshot *Data is delayed at least 15 minutes